The Current Ratio as of September 2024 (TTM) for Oncternal Therapeutics, Inc. (ONCT) is 2.89

According to Oncternal Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 2.89. This represents a change of -49.20% compared to the average of 5.68 of the last 4 quarters.

Oncternal Therapeutics, Inc. (ONCT) Historical Current Ratio (quarterly & annually)

How has ONCT Current Ratio performed in the past?

The mean historical Current Ratio of Oncternal Therapeutics, Inc. over the last ten years is 7.53. The current 2.89 Current Ratio has changed 3.74% with respect to the historical average. Over the past ten years (40 quarters), ONCT's Current Ratio was at its highest in in the December 2020 quarter at 20.14. The Current Ratio was at its lowest in in the June 2015 quarter at 0.56.

Oncternal Therapeutics, Inc. (ONCT) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Oncternal Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Oncternal Therapeutics, Inc. (ONCT) Average Current Ratio

How has ONCT Current Ratio performed in the past?

The current Current Ratio of Oncternal Therapeutics, Inc. (ONCT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Oncternal Therapeutics, Inc. (ONCT) Current Ratio vs. Peers

How is ONCT’s Current Ratio compared to its peers?

Oncternal Therapeutics, Inc.’s Current Ratio is less than Neoleukin Therapeutics, Inc. (0), less than CytomX Therapeutics, Inc. (15.33), greater than Assembly Biosciences, Inc. (1.00), greater than Instil Bio, Inc. (2.74), less than Nuvation Bio Inc. (15.06), less than Protara Therapeutics, Inc. (11.49), less than Vaccinex, Inc. (16.33), greater than Monopar Therapeutics Inc. (0.42), less than Miromatrix Medical Inc. (6.59), less than Surrozen, Inc. (3.46), less than Passage Bio, Inc. (6.96), less than Absci Corporation (7.67), less than Adverum Biotechnologies, Inc. (6.49), less than Kezar Life Sciences, Inc. (7.99), less than Armata Pharmaceuticals, Inc. (9.58), greater than Pasithea Therapeutics Corp. (0.25), less than Aditxt, Inc. (6.20), greater than null (0.07),

Build a custom stock screener for Oncternal Therapeutics, Inc. (ONCT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncternal Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Oncternal Therapeutics, Inc. (ONCT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Oncternal Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.